This company has been marked as potentially delisted and may not be actively trading. Edge Therapeutics (EDGE) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock EDGE vs. MOR, GMTX, CALT, MENS, ZYME, SBTX, MBX, AVTE, NLTX, and CYBNShould you be buying Edge Therapeutics stock or one of its competitors? The main competitors of Edge Therapeutics include MorphoSys (MOR), Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Jyong Biotech (MENS), Zymeworks (ZYME), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), and Cybin (CYBN). Edge Therapeutics vs. Its Competitors MorphoSys Gemini Therapeutics Calliditas Therapeutics AB (publ) Jyong Biotech Zymeworks Silverback Therapeutics MBX Biosciences Aerovate Therapeutics Neoleukin Therapeutics Cybin Edge Therapeutics (NASDAQ:EDGE) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations. Which has more risk & volatility, EDGE or MOR? Edge Therapeutics has a beta of 3.65, indicating that its stock price is 265% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Which has preferable earnings & valuation, EDGE or MOR? Edge Therapeutics has higher earnings, but lower revenue than MorphoSys. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdge TherapeuticsN/AN/A-$40.86MN/AN/AMorphoSys$238.28M11.99-$205.35M-$3.48-5.45 Does the media prefer EDGE or MOR? In the previous week, Edge Therapeutics' average media sentiment score of 0.00 equaled MorphoSys'average media sentiment score. Company Overall Sentiment Edge Therapeutics Neutral MorphoSys Neutral Is EDGE or MOR more profitable? Edge Therapeutics has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Edge Therapeutics' return on equity of -81.29% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets Edge TherapeuticsN/A -81.29% -56.92% MorphoSys -226.79%-694.31%-22.55% Do insiders and institutionals have more ownership in EDGE or MOR? 28.0% of Edge Therapeutics shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 37.1% of Edge Therapeutics shares are owned by insiders. Comparatively, 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryEdge Therapeutics beats MorphoSys on 6 of the 8 factors compared between the two stocks. Get Edge Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EDGE and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDGE vs. The Competition Export to ExcelMetricEdge TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.27B$763.52M$5.47B$9.53BDividend YieldN/A4.84%4.74%4.08%P/E RatioN/A1.3428.6723.80Price / SalesN/A25.20422.2688.08Price / CashN/A19.5635.4557.96Price / Book42.446.778.275.55Net Income-$40.86M-$4.28M$3.24B$259.03M Edge Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDGEEdge TherapeuticsN/A$40.32-1.4%N/A+1,048.5%$1.27BN/A0.00N/AMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730GMTXGemini TherapeuticsN/A$60.58-0.6%N/A+38.5%$2.62BN/A-60.5830High Trading VolumeCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180MENSJyong BiotechN/A$13.80+17.1%N/AN/A$1.05BN/A0.0031Positive NewsQuiet Period ExpirationZYMEZymeworks2.8532 of 5 stars$13.33-4.9%$21.00+57.5%+24.3%$928.87M$93.38M-8.89460Upcoming EarningsSBTXSilverback TherapeuticsN/A$17.92-0.4%N/A+68.5%$646.16MN/A-7.4083High Trading VolumeMBXMBX Biosciences2.6288 of 5 stars$14.57+11.8%$37.57+157.9%N/A$486.99MN/A0.0036Positive NewsGap UpHigh Trading VolumeAVTEAerovate TherapeuticsN/A$8.33-4.4%N/A-88.5%$241.45MN/A-2.7920High Trading VolumeNLTXNeoleukin TherapeuticsN/A$22.81-1.2%N/A-46.3%$214.37MN/A-7.3390CYBNCybin2.7265 of 5 stars$7.99-0.6%$85.00+963.8%N/A$188.48MN/A-1.8250Gap Down Related Companies and Tools Related Companies MorphoSys Competitors Gemini Therapeutics Competitors Calliditas Therapeutics AB (publ) Competitors Jyong Biotech Competitors Zymeworks Competitors Silverback Therapeutics Competitors MBX Biosciences Competitors Aerovate Therapeutics Competitors Neoleukin Therapeutics Competitors Cybin Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EDGE) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edge Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edge Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EDGE Stock Alerts